NEW YORK – HTG Molecular Diagnostics reported after the close of the market on Wednesday that its first quarter revenues dropped 31 percent year over year.
For the three months ended March 31, the Tucson, Arizona-based firm's revenues fell to $2.2 million from $3.2 million in the same period the year before, due to the impact of the COVID-19 pandemic requiring the closure of customer facilities around the globe. The firm missed the consensus Wall Street estimate of $3.0 million.